Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,718 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Interaction Clear all
Recruiting Not applicable Interventional

Characterizing the Impact of Presbyphonia on Social Interaction

NCT06441136
View directory record Official record
Conditions
Presbyphonia
Interventions
PhoRTE Program, University of California Los Angeles (UCLA) Loneliness Scale, Social Disconnectedness Scale, Patient Health Questionnaire 9, Aging Voice Index, The Edmonton Frail Scale, Vocal Effort Scale, Montreal Cognitive Assessment, Voice Handicap Index-10, Voice Problem Impact Scales, Cough Severity Index, Laryngoscopy, Acoustic, perceptual, and aerodynamic assessments
Other · Procedure
Lead sponsor
Matthew R. Hoffman
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

NCT02947711
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2027, Diltiazem ER
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 28, 2026, 3:09 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke

NCT07531264
View directory record Official record
Conditions
Chronic Stroke-related Upper-extremity Motor Impairment, Motor Module-guided Rehabilitation Targeting Impaired Intermuscular Coordination and Motor Recovery
Interventions
Neuromuscular coordination enhancement (NICE) intervention, EMG Amplitude Biofeedback Exercise
Other
Lead sponsor
University of Houston
Other
Eligibility
21 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

NCT05615012
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin
Drug · Dietary Supplement
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

NCT02705963
View directory record Official record
Conditions
Solid Tumors
Interventions
Trametinib, Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doravirine, Rifapentine and Isoniazid Interaction

NCT03886701
View directory record Official record
Conditions
Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
Interventions
Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

NCT04138836
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877, Midazolam, Itraconazole, Esomeprazole
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 28, 2026, 3:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Leveraging Interactive Digital Technology to Increase Access to Family-Based Behavioral Treatment for Childhood Obesity

NCT06728800
View directory record Official record
Conditions
Childhood Obesity
Interventions
FBT 2.0, Delayed-Start Control (AAP educational materials)
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
6 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional

Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study

NCT01348880
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Vardenafil ODT, (Staxyn, BAY38-9456), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
65 Years to 80 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

NCT00434486
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2007 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCT07305779
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-380135, Quinidine Gluconate
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Whole Selves User Testing and Feasibility Study

NCT06392542
View directory record Official record
Conditions
Alcohol Use, Unspecified, Relationship, Social, Depression, Anxiety
Interventions
Whole Selves
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 30 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Observing Infant Feeding Interactions

NCT02517970
View directory record Official record
Conditions
Classical Music, Television Show
Interventions
Technology distraction
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
Up to 6 Months
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

NCT01218620
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 28, 2026, 3:09 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, Smallpox and Mpox Vaccine, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 42 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Not applicable Interventional Results available

Interactive Obesity Treatment Approach for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI

NCT03980743
View directory record Official record
Conditions
Obesity, Overweight, Severe Mental Disorder
Interventions
iOTA text messaging intervention, Health Education text messaging intervention
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 28, 2026, 3:09 AM EDT
Withdrawn Not applicable Interventional

Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination

NCT01493258
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
iCOPE Intervention group
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 28, 2026, 3:09 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.

NCT03298334
View directory record Official record
Conditions
Cesarean Delivery Affecting Newborn, Obesity, Childhood, Intestinal Microbiome, Microbiota, Host Microbial Interactions, Gastrointestinal Microbiome
Interventions
Vaginal Seeding, No Vaginal Seeding
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 50 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 3:09 AM EDT
Withdrawn No phase listed Observational

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

NCT00573092
View directory record Official record
Conditions
Myocardial Infarction, Cerebrovascular Accident, Death, Sudden, Cardiac
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

NCT07279233
View directory record Official record
Conditions
Healthy, Volunteer
Interventions
Mirdametinib, Mirdametinib and Carbamazepine
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fear and Avoidance in PTSD Patients

NCT04770584
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Fear Conditioning, Avoidance conditioning, Pavlovian fear extinction learning, Willingness to pay to avoid shock
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

NCT05906836
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 28, 2026, 3:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Lorcaserin, Placebo, Cocaine Infusion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 28, 2026, 3:09 AM EDT